Last edition
News about "Eli Lilly and Company "
Lilly and EVA Pharma Secure Approval to Distribute Locally Manufactured Insulin in Egypt
Under this agreement, Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges.
Eli Lilly And Company | 18/12/2024 | By Aishwarya
Lilly to Invest USD 3 Billion to Expand its Manufacturing Facility in Wisconsin
Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location.
Eli Lilly And Company | 06/12/2024 | By Aishwarya
Lilly Gets FDA Approval for EBGLYSS for Atopic Dermatitis
Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.
Eli Lilly And Company | 17/09/2024 | By Aishwarya
Lilly to Expand its Manufacturing Site in Ireland with USD 1.8 Billion Investment
The company also unveiled its new USD 800 million facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for Lilly's latest diabetes and obesity treatments.
Eli Lilly And Company | 13/09/2024 | By Aishwarya
Lilly Completes Acquisition of Morphic
Morphic is a biopharmaceutical company developing oral integrin therapies for the treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
Eli Lilly And Company | 17/08/2024 | By Aishwarya | 125
Lilly to Acquire Morphic to Enhance Outcomes for Patients with IBD
Eli Lilly and Company has signed a definitive agreement to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for the treatment of serious chronic diseases.
Eli Lilly And Company | 09/07/2024 | By Aishwarya | 159
Lilly and OpenAI to Revolutionize Medicines to Treat Drug-Resistant Bacteria
Eli Lilly and Company has signed a collaboration deal with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
Eli Lilly And Company | 26/06/2024 | By Aishwarya | 216
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy